B. Rouveix, MD, PhD; F. Bricaire, MD; C Michon, MD; G. Franssen, BS; J Lebras, PharmD; Hôpital C. Bernard; J. Bernard, MD; F. Ajana, MD; J. L. Vienne, MD
To the editor: Mefloquine, a quinolinemethanol derivative with a long half-life, is an effective therapy for chloroquine-resistant falciparum malaria and a relatively effective therapy for acute malaria. Three cases of confusion from severe acute toxicity have been reported, although they are not well documented (1, 2). We report five cases of an acute brain syndrome after mefloquine therapy in patients who returned from Africa (three patients from Gabon, one from Cameroon, and one from the Ivory Coast).
Four men, aged 19, 20, 22, and 55 years, respectively, and one girl, aged 5 years, had an acute brain syndrome. None had
Rouveix B, Bricaire F, Michon C, Franssen G, Lebras J, Bernard HC, et al. Mefloquine and an Acute Brain Syndrome. Ann Intern Med. ;110:577–578. doi: 10.7326/0003-4819-110-7-577
Download citation file:
Published: Ann Intern Med. 1989;110(7):577-578.
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use